6PPD-quinone exposure and Alzheimer’s disease: insights from integrative network pharmacology, transcriptomics, machine learning, and molecular docking

Read full text
Authors: Chun Zhang, J Zhang
Cited by: 1
References: 52

Abstract

Abstract Objectives To systematically investigate the molecular associations between 6PPD-quinone (6PPD-Q), an environmental transformation product of the tire antioxidant 6PPD, and Alzheimer’s disease (AD) pathogenesis. Methods An integrative strategy combining network pharmacology, transcriptomic validation, and machine learning was employed. Intersecting targets were identified through multi-database mining, followed by functional enrichment and protein–protein interaction (PPI) network analyses. Transcriptomic validation, SHAP-based XGBoost analysis, Mendelian randomization, and molecular docking were performed to evaluate target expression, diagnostic value, causal associations, and binding affinities. Results A total of 92 intersecting targets were identified, enriched in synaptic structures, kinase activity, neuroinflammation, and apoptotic pathways. PPI analysis revealed 23 core targets, with NFKB1 , GSK3B , and PIK3CA as key hub genes enriched in the cerebral cortex and basal ganglia. Transcriptomic data confirmed differential expression of core targets in AD. SHAP analysis identified PTGS2 , KIT , PIK3CA , NFE2L2 , and NFKB1 as high-value diagnostic predictors. Mendelian randomization supported a causal association between NFKB1 brain expression and AD risk. Molecular docking confirmed strong binding of 6PPD-Q to PTGS2 , GSK3B , and NFE2L2 . Conclusions This study provides the first systematic characterization of the molecular mechanisms by which 6PPD-Q may contribute to AD pathogenesis, potentially through inducing oxidative stress, activating neuroinflammation, and disrupting kinase signaling networks.

Fields of Study & Subjects

Genomics phytochemicals and oxidative stress Sirtuins and Resveratrol in Medicine Tryptophan and brain disorders

Publication details

Journal / source
Open Medicine
Publisher
Walter de Gruyter GmbH
Volume
21
Issue
1
Pages
20261477–20261477
Publication date
1 January 2026
Language
EN